Novo Nordisk's Pipeline Deepens as Amycretin and MASH Data Bolster a Stretched Stock

Novo Nordisk is quietly assembling a multi-pronged assault on metabolic disease that reaches far beyond the Wegovy juggernaut. Two new clinical updates — one on the experimental dual-agonist Amycretin and the other on Semaglutide's efficacy in a severe fatty liver condition — underscore how the Danish drugmaker is trying to turn its GLP-1 platform into a broad arsenal. Yet the share price tells a more cautious story, with the stock at €38.28 on Wednesday, down nearly 5% on the week and 37% over the past twelve months.

Semaglutide Scores in MASH as Wegovy Data Pile Up

The most immediate catalyst comes from the Phase 3 ESSENCE programme, where Semaglutide 2.4 mg significantly reduced liver inflammation and fibrosis in patients with metabolic dysfunction-associated steatohepatitis — a condition that often goes undiagnosed until it progresses to cirrhosis or liver failure. Subgroup analyses have now added granularity, including data on Japanese patients and postmenopausal women. The readout will be presented at the EASL Congress in Barcelona at the end of May, with an R&D event on the ADA conference schedule for 7 June 2026.

Separately, the STEP-UP study on Wegovy at a 7.2 mg weekly dose delivered a 27.7% average weight loss among early responders after 72 weeks, and 21% across the roughly 1,400 participants. Dropout rates due to side effects were no higher than with the lower dose. Novo Nordisk also highlighted that most of the weight lost came from fat, with skeletal muscle largely preserved — a differentiator in a field where body composition is becoming a key metric.

Amycretin Targets Weight Maintenance — an Untapped Corner

While Wegovy dominates the current market, the company is already laying groundwork for the next generation. On 18 May 2026, Novo Nordisk activated the AMAZE-12 Phase 3 study for Amycretin (internal code NNC0487-0111), a once-weekly subcutaneous peptide that simultaneously activates GLP-1 and amylin receptors. Unlike most obesity trials, AMAZE-12 is not about initial weight loss but about stabilising weight after the reduction phase — a commercially distinct goal that few competitors have addressed.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

The clinical foundation is solid. A Phase 1b/2a study of injectable Amycretin yielded 22% weight loss at 36 weeks, while an oral formulation produced 13.1% after 12 weeks in a separate Phase 1 trial. The broader AMAZE Phase 3 programme, including the AMAZE-1 study measuring weight change over 84 weeks, is now formally launched.

CagriSema and the Regulatory Calendar Tighten

Alongside Amycretin, the Cagrilintide-Sema glutide combination CagriSema remains the nearer-term pipeline bet. The larger REDEFINE-11 Phase 3 trial is expected to deliver data in the first half of 2027, while a higher-dose Phase 3 study is slated to start in the second half of 2026. The US Food and Drug Administration is scheduled to review a CagriSema approval application sometime this year, making the regulatory calendar unusually dense. Meanwhile, a mechanistic study of Cagrilintide alone is probing how the drug affects food intake and hunger, feeding into the design of future therapies.

In the first quarter of 2026 alone, Novo Nordisk secured six regulatory approvals and initiated more than ten clinical trials. International obesity revenue, currency-adjusted, jumped 44% in the same period, and the company claims a 55% volume share of weekly injectable GLP-1 therapies.

Novo Nordisk at a turning point? This analysis reveals what investors need to know now.

Defensive Guidance Belies Pipeline Optimism

Despite the clinical momentum, the 2026 outlook remains subdued. Novo Nordisk now expects a 4% to 12% decline in currency-adjusted revenue and operating profit — a slight improvement from the previous forecast of 5% to 13%, but still a marked contraction. The tension between near-term profit headwinds and a swelling pipeline is what keeps the stock under pressure.

Investors will get the next big test when the MASH data hit Barcelona later this month. If Semaglutide can convincingly demonstrate efficacy in a large new indication, it would strengthen the argument that Wegovy is more than just an obesity drug — and that the platform's full value has yet to be priced in.

Ad

Novo Nordisk Stock: New Analysis - 20 May

Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis...

en | DK0062498333 | NOVO | boerse | 69381363 |